1. Risk of strong antibody decline in dialysis and transplant patients after SARS-CoV-2mRNA vaccination: Six months data from the observational Dia-Vacc study
- Author
-
Julian Stumpf, Jörg Schwöbel, Tom Lindner, Leona Anders, Torsten Siepmann, Claudia Karger, Jan Hüther, Heike Martin, Petra Müller, Robert Faulhaber-Walter, Torsten Langer, Holger Schirutschke, Thomas Stehr, Frank Meistring, Annegret Pietzonka, Kirsten Anding-Rost, Katja Escher, Frank Pistrosch, Jens Schewe, Harald Seidel, Kerstin Barnett, Thilo Pluntke, Simon Cerny, Alexander Paliege, Ingolf Bast, Anne Steglich, Florian Gembardt, Friederike Kessel, Hannah Kröger, Patrick Arndt, Jan Sradnick, Kerstin Frank, Anna Klimova, René Mauer, Xina Grählert, Torsten Tonn, and Christian Hugo
- Subjects
Oncology ,Health Policy ,Internal Medicine - Abstract
Vulnerable dialysis and kidney transplant patients show impaired seroconversion rates compared to medical personnel eight weeks after SARS-CoV-2mRNA vaccination.We evaluated six months follow up data in our observational Dia-Vacc study exploring specific cellular (interferon-γ release assay) or/and humoral immune responses after 2x SARS-CoV-2mRNA vaccination in 1205 participants including medical personnel (125 MP), dialysis patients (970 DP) and kidney transplant recipients (110 KTR) with seroconversion (Six months after vaccination, seroconversion remained positive in 98% of MP, but 91%/87% of DP/KTR (Both vulnerable DP and KTR groups are at risk for a strong decline for IgG and RBD antibodies. In KTR, antibody titres peak at a markedly lower level and accelerated antibody decline is mixed with a delayed/increasing IgG, RBD-IgG, or cellular immune response in a 16% fraction of patients. In both populations, immune monitoring should be used for early timing of additional booster vaccinations.This study was funded by the Else Kröner Fresenius Stiftung, Bad Homburg v. d. H., grant number Fördervertrag EKFS 2021_EKSE.27.
- Published
- 2022